WebA Hillevax Inc Senior Scientist's compensation ranges from $130,751 to $157,117, with an average salary of $138,743. Salaries can vary widely depending on the region, the department and many other important factors such as the employee’s level of education, certifications and additional skills. WebCompany Type For Profit. Contact Email [email protected]. Phone Number (617) 213-5054. HilleVax is a biopharmaceutical company that focuses on the development and …
Did you know?
WebMay 2, 2024 · HilleVax, Inc. (Nasdaq: HLVX), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, reported today dosing of the first subjects in its previously announced Phase 2b clinical trial of HIL-214, the company’s virus-like particle (VLP) based vaccine candidate, for the prevention of … WebMar 13, 2024 · HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
WebLife At Hillevax; Investors and Media. Overview; News & Events; Stock Information; Corporate Governance; Financial Information; IR Resources; Contact Us Rob Hershberg, M.D., Ph.D., is President, Chief Executive Officer and chairman of … Norovirus. Norovirus is the most common cause of viral acute gastroenteritis (AGE) … HilleVax has no obligation to provide any form of compensation in return for any … BOSTON, March 17, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: … Get in touch to find out more about HilleVax. 75 State St., Suite 100, Boston, … BOSTON, March 17, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: … Stock Information - Hillevax - Advancing a Vaccine to Protect Against Norovirus Corporate Governance - Hillevax - Advancing a Vaccine to Protect Against … Financial Information - Hillevax - Advancing a Vaccine to Protect Against Norovirus HilleVax priced its initial public offering on April 29, 2024. What is HilleVax’s fiscal … WebHilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle …
WebDavid L. Swerdlow MD (CAPT. USPHS, retired) joined HilleVax Inc. as VP Medical and Governmental Affairs in February, 2024. He retired from … WebMay 3, 2024 · Davis Polk advised the joint book-running managers in connection with the upsized initial public offering of 11,765,000 shares of common stock of HilleVax, Inc. at $17.00 per share for total gross proceeds of approximately $200 million. The common stock is listed on the Nasdaq Global Select...
WebMar 17, 2024 · BOSTON, March 17, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. HLVX, a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...
WebApr 6, 2024 · HilleVax, Inc. Initial Offering (FormS) Accepted: April 6, 2024 at 8:23 PM UTC. duodenal infectionWebSep 8, 2024 · BOSTON--(BUSINESS WIRE)--HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine … cry peace and safetyWebDec 7, 2024 · Hillevax Inc is a pharmaceutical company that caught the eye of investors with its recent IPO. It’s an American startup headquartered in Boston, Massachusetts, It’s a … duodenal mucosa with peptic injuryWebAbout HilleVax, Inc. 75 STATE STREET SUITE 100 - 9995, BOSTON, Massachusetts, 2109, United States +1 617 213-5054. HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on ... duodenal gland secretion preventsWebApr 6, 2024 · Get Hillevax Inc (HLVX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. cry peace peace then sudden destructionWebNorovirus is responsible for greater than 90% of epidemic non-bacterial outbreaks of gastroenteritis. [1, 2] 700 M+. Norovirus is estimated to cause approximately 700 million cases of gastroenteritis and 200,000 deaths worldwide annually. [3] $ 60 B+. The global economic burden of norovirus is estimated to be $60.3 billion annually. cry peace peace but there is no peaceWebGet the latest Hillevax Inc (HLVX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. duodenal mass ct scan